Linola H N (Prednisolone)

Prednisolone binds to glucocorticoid receptors inside skin cells, altering gene transcription. This leads to reduced production of inflammatory cytokines, decreased leukocyte migration, and suppression of the local immune response, thereby relieving redness, swelling and itching.

The appropriate dose and frequency are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient‑specific factors. Patients should follow the healthcare professional’s instructions exactly.

Safety in pregnancy and lactation has not been fully established for topical prednisolone. The prescriber should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Linola H N contains prednisolone, which is a mid‑potency corticosteroid. Compared with low‑potency agents (e.g., hydrocortisone) it offers stronger anti‑inflammatory effects, while being less potent than high‑potency steroids such as clobetasol, potentially offering a balance between efficacy and safety for moderate skin inflammation.

Store Linola H N at room temperature, ideally below 25 °C. Keep the tube or container tightly closed, protect it from moisture and direct sunlight, and store it in its original packaging until use.

Apply a thin layer of the cream or ointment to the affected skin area, gently massaging it in until fully absorbed. Follow the frequency and duration prescribed by the healthcare professional, and avoid applying to broken skin unless directed.

Serious risks include skin atrophy, formation of striae, secondary infections, and systemic adrenal suppression, especially when used over large body areas, for prolonged periods, or under occlusive dressings. Patients should report any signs of systemic effects, such as fatigue or unexplained weight loss, to their clinician.

Linola H N should be avoided in individuals with known hypersensitivity to prednisolone or any excipients, in untreated bacterial, viral or fungal skin infections, and in patients where systemic corticosteroid exposure is contraindicated unless a prescriber decides otherwise.